Partial Characterization of an Autoantibody Recognizing the Secondary Binding Site(s) of Thrombin in a Patient with Recurrent Spontaneous Arterial Thrombosis
J M Costa
Laboratoire d’Hémostase et Centre Claude Bernard de Recherche sur les Maladies vasculaires périphériques, Hôpital Broussais, Paris, France
,
J N Fiessinger
Laboratoire d’Hémostase et Centre Claude Bernard de Recherche sur les Maladies vasculaires périphériques, Hôpital Broussais, Paris, France
,
L Capron
Laboratoire d’Hémostase et Centre Claude Bernard de Recherche sur les Maladies vasculaires périphériques, Hôpital Broussais, Paris, France
,
M Aiach
Laboratoire d’Hémostase et Centre Claude Bernard de Recherche sur les Maladies vasculaires périphériques, Hôpital Broussais, Paris, France
A patient with an 18 year history of recurrent arterial thrombosis and no evidence of atherosclerosis or embolism of cardiac origin presented with a prolonged thrombin clotting time when performed with human thrombin. The bovine thrombin clotting time was only slightly prolonged. During 30 months of follow-up, the thrombin time fluctuated, but remained prolonged. The patient has been treated with an oral anticoagulant for the past 8 years, with no thrombotic recurrence.
The inhibitor activity was due to the presence of polyclonal IgGs which bound to thrombin-Sepharose. The influence of IgGs purified from the patient’s serum was compared to the influence of normal IgGs in several systems exploring the catalytic activity of thrombin and the binding of the enzyme to macromolecular substrates through secondary binding site(s). We found that the IgGs did not impair the catalytic activity toward small synthetic substrates, but inhibited the binding of thrombin to fibrinogen, thrombomodulin and heparin cofactor II. Such proteins are known to require a secondary binding site of thrombin to interact with the enzyme.
The anti-thrombin antibody might have resulted from an abnormal generation of thrombin. This would be the consequence of the process favouring thrombosis. Alternatively, the autoantibody might have favoured thrombosis primarily, by impairing natural antithrombotic mechanisms triggered by thrombin.
References
1
Machovich R,
Horvath I.
Thrombin and haemostasis: Regulation of the biological functions of thrombin. (Facts and perspectives.). Haematologia 1981; 14: 339-359
2
Fenton II JW.
Bioregulatory functions of thrombin. Part I. Structure of thrombin and thrombin derivatives. Thrombina
. Ann NY Acad Sci 1986; 485: 5-15
7
Aiach M,
Léon M,
Michaud A,
Capron L.
Adaptation of synthetic peptide substrate based assays on a discrete analyzer. Semin Thromb Haemostas 1983; 9: 206-216
10
Comb PC,
Doray D,
Patton D,
Esmon CT.
An abnormal plasma distribution of protein S occurs in functional protein S deficiency. Blood 1986; 67: 504-508
15
De Roux N,
Chadeuf G,
Molho-Sabatier P,
Plouin PF,
Aiach M.
Clinical and biochemical characterization of AT III Franconville, a variant with Pro 41 Leu mutation. Br J Haematol 1990; 75: 222-227
17
Loeliger A,
Hers JFP.
Chronic antithrombinaemia (antithrombin V) with haemorrhagic diathesis in a case of rheumatoid arthritis with hypergammaglobulinaemia. Thromb Diath Haemorrh 1957; 1: 499-528
18
Strieker RB,
Lane PK,
Leffert JD,
Rodgers GM,
Shuman MA,
Corash L.
Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood 1988; 72: 1375-1380
20
Flaherty MJ,
Henderson R,
Wener MH.
Iatrogenic immunization with bovine thrombin: A mechanism for prolonged thrombin times after surgery. Ann Intern Med 1989; 111: 631-634
21
Zehnder JL,
Leung LLK.
Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76: 2011-2016
23
Hawiger J,
Hanicki Z,
Struzick T.
On the immunologic nature of antithrombin in the course of lupus erythematosus disseminatus. Acta Med Polona 1964; 5: 53-60
29
Fenton II JW,
Olson TA,
Zabinski MP,
Wilner GD.
Anion-binding exosite of human a-thrombin and fibrin(ogen) recognition. Biochemistry 1988; 27: 7106-7112
31
Boissel JP,
Le Bonniec B,
Rabiet MJ,
Labié D,
Elion J.
Covalent structures of an autolytic derivative of human a-thrombin. J Biol Chem 1984; 259: 5691-5697
32
Noé G,
Hofsteenge J,
Rovelli G,
Stone SR.
The use of sequence-specific antibodies to identify a secondary binding site in thrombin. J Biol Chem 1988; 263: 11729-11735
34
Lord ST,
Byrd PA,
Hede HL,
Wei C,
Colby TJ.
Analysis of fibrinogen A - fusion proteins. Mutants which inhibit thrombin equivalently are not equally good substrates. J Biol Chem 1990; 265: 838-843
35
Preissner KT,
Koyama T,
Müller D,
Tschopp J,
Müller-Berghaus G.
Domain structure of the endothelial cell receptor thrombomodulin as deduced from modulation of its anticoagulant functions. Evidence for a glycosaminoglycan-dependent secondary binding site for thrombin. J Biol Chem 1990; 265: 4915-4922
36
Bourin MC,
Lindahl U.
Functional role of the polysaccharide component of rabbit thrombomodulin proteoglycan. Effects on inactivation of thrombin by antithrombin, cleavage of fibrinogen by thrombin and thrombin-catalyzed activation of factor V. Biochem J 1991; 270: 419-425
38
Hortin GL,
Banutto BM.
Inhibition of thrombin’s clotting activity by synthetic peptide segments of its inhibitors and substrates. Biochem Biophys Res Commun 1990; 169: 437-441
40
Maruyama I,
Majerus PW.
The turnover of thrombin-thrombomodulin complex in cultured human umbilical vein endothelial cells and A549 lung cancer cells. Endocytosis and degradation of thrombin. J Biol Chem 1985; 260: 15432-15438
42
Pizzo SV.
Serpin receptor 1: A hepatic receptor that mediates the clearance of antithrombin Ill-proteinase complexes. Am J Med 1984; 87 Suppl (03) B 10-14
